Pfizer CEO: 99 percent chance Delta-specific vaccine won't be necessary

Right now it doesn't seem like a Delta variant-specific COVID-19 vaccine will be necessary because the original shot is holding up well, Pfizer CEO Albert Bourla said Tuesday during an interview with The Atlantic.
However, he added that the company will continue to tweak its vaccine to stay ahead of the curve in case things change. "We are in the middle of the process of producing a specific for Delta variant vaccine," he said. "It is 99.9 percent [probable] that we will not need it."
Bourla's confidence in the current vaccine seems to line up with other experts, who don't expect to be seeing a vaccine tailored to Delta anytime soon, even for potential first doses for people who remain unvaccinated. Vox's Sigal Samuel explored the question in a report published Monday, revealing that infectious disease specialists and virologists don't believe the updated vaccines will be needed and could even lead to manufacturing mixups if they're mass-produced. Plus, the regulatory process would simply take up time "that right now we don't have," said Angela Rasmussen, a virologist at the University of Saskatchewan.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Still, there's agreement that tinkering with the mRNA technology, which can be updated and produced more quickly, will come in handy, especially in the long run because it allows researchers to identify potential hiccups in the process. At the end of the day, it's best to be prepared. Read more at Vox.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
America's favorite fast food restaurants
The Explainer There are different ways of thinking about how Americans define how they most like to spend their money on burgers, tacos and fried chicken
-
Law: The battle over birthright citizenship
Feature Trump shifts his focus to nationwide injunctions after federal judges block his attempt to end birthright citizenship
-
The threat to the NIH
Feature The Trump administration plans drastic cuts to medical research. What are the ramifications?
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr.: A new plan for sabotaging vaccines
Feature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
Unraveling autism: RFK Jr.'s vow to find a root cause
Feature RFK Jr. has vowed to find the root cause of the 'autism epidemic' in months. Scientists have doubts.
-
The sneaking rise of whooping cough
Under the Radar The measles outbreak isn't the only one to worry about
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia